Apr 17
A Anvisa aprovou o inavolisibe, terapia oral inovadora para câncer de mama com mutação PIK3CA. O tratamento reduz progressão da doença, prolonga o controle clínico e amplia opções personalizadas de cuidado.
seen from United States
seen from United States
seen from Türkiye
seen from Türkiye
seen from United States
seen from Brazil
seen from Canada
seen from United States
seen from United States
seen from United States
seen from Russia
seen from Brazil
seen from United States
seen from Yemen
seen from Brazil
seen from Canada
seen from United States
seen from Canada
seen from South Africa
seen from United Kingdom
A Anvisa aprovou o inavolisibe, terapia oral inovadora para câncer de mama com mutação PIK3CA. O tratamento reduz progressão da doença, prolonga o controle clínico e amplia opções personalizadas de cuidado.
A Agência Nacional de Vigilância Sanitária aprovou o Inavolisibe, da Roche Farma, ampliando opções para câncer de mama avançado com mutação PIK3CA.
FDA Memberikan Peninjauan Prioritas untuk Inavolisib dalam Pengobatan Kanker Payudara dengan Mutasi PIK3CA
Majalah Farmasetika – Peninjauan prioritas inavolisib adalah untuk pengobatan pasien dengan kanker payudara lanjut yang reseptor hormonnya positif, HER2-negatif dengan mutasi PIK3CA. FDA telah memberikan peninjauan prioritas untuk inavolisib (GDC-0077; Roche) dalam kombinasi dengan palbociclib (Ibrance; Pfizer) dan fulvestrant (Faslodex; AstraZeneca), mempercepat aksesibilitas bagi pasien yang…
View On WordPress